부산대학교 도서관

Background: Acute leukemia of ambiguous lineage (ALAL) is infrequent in occurrence with research data available only as small case series, thus leading to a diverse approach in the management. Using "Acute lymphoblastic leukemia (ALL)- type" induction therapy along with a tyrosine kinase inhibitor for t (9,22) has achieved higher remission rates with less toxicity compared with the more intensive AML induction chemotherapy in many case series. The role of immunophenotypic and genetic markers in directing chemotherapy and the utility of targeted therapy is still unknown. In current study, 12 patients who were diagnosed with ALAL have been retrospectively analyzed for patient demographics, hematopathological profile and induction outcomes. Among 12 patients, there were 9 male and 3 female. 25% of the patients showed t (9,22) and 16.6% showed other cytogenetic abnormalities. 5 patients showed remission after induction, 5 failed after induction, 1 expired before induction and 1 deferred chemotherapy. 50% of the patients who were started on ALL- type induction chemotherapy have shown good outcomes. Prospective studies are required to establish the best therapeutic approach in this heterogeneous disease. [ABSTRACT FROM AUTHOR]